Detection rates of 18F-FDG and 68Ga-DOTA-peptide PET/CT scans are stratified by histology and SUVmax-thresholds
| PET-CT . | Detection rate (SUVmax cut-off: 2.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 54% (28/52) (95% CI 40–68) | 51% (23/45) (95% CI 36–62) | 71% (5/7) (95% CI 50–92) | 0.3158 |
| 68Ga-DOTA-peptide | 88% (23/26) (95% CI 69–97) | 92% (22/24) (95% CI 63–100) | 50% (1/2) (95% CI 25–82) | 0.0764 |
| P-value | 0.0025 | 0.0008 | 0.5708 | |
| PET-CT . | Detection rate (SUVmax cut-off: 2.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 54% (28/52) (95% CI 40–68) | 51% (23/45) (95% CI 36–62) | 71% (5/7) (95% CI 50–92) | 0.3158 |
| 68Ga-DOTA-peptide | 88% (23/26) (95% CI 69–97) | 92% (22/24) (95% CI 63–100) | 50% (1/2) (95% CI 25–82) | 0.0764 |
| P-value | 0.0025 | 0.0008 | 0.5708 | |
| PET-CT . | Detection rate (SUVmax cut-off: 1.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 81% (42/52) (95% CI 68–93) | 81% (36/45) (95% CI 66–92) | 86% (6/7) (95% CI 53–97) | 0.7213 |
| 68Ga-DOTA-peptide | 100% (26/26) (95% CI 81–100) | 100% (24/24) (95% CI 79–100) | 50% (1/2) (95% CI 25–82) | 0.0004 |
| P-value | 0.0166 | 0.0188 | 0.2840 | |
| PET-CT . | Detection rate (SUVmax cut-off: 1.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 81% (42/52) (95% CI 68–93) | 81% (36/45) (95% CI 66–92) | 86% (6/7) (95% CI 53–97) | 0.7213 |
| 68Ga-DOTA-peptide | 100% (26/26) (95% CI 81–100) | 100% (24/24) (95% CI 79–100) | 50% (1/2) (95% CI 25–82) | 0.0004 |
| P-value | 0.0166 | 0.0188 | 0.2840 | |
ACs: atypical carcinoids; CI: confidence interval; CT: computed tomography; FDG: 18Fluorodeoxyglucose; PCs: pulmonary carcinoids; PET: positron emission tomography; SUVmax: maximum standardized uptake value; TCs: typical carcinoids.
Detection rates of 18F-FDG and 68Ga-DOTA-peptide PET/CT scans are stratified by histology and SUVmax-thresholds
| PET-CT . | Detection rate (SUVmax cut-off: 2.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 54% (28/52) (95% CI 40–68) | 51% (23/45) (95% CI 36–62) | 71% (5/7) (95% CI 50–92) | 0.3158 |
| 68Ga-DOTA-peptide | 88% (23/26) (95% CI 69–97) | 92% (22/24) (95% CI 63–100) | 50% (1/2) (95% CI 25–82) | 0.0764 |
| P-value | 0.0025 | 0.0008 | 0.5708 | |
| PET-CT . | Detection rate (SUVmax cut-off: 2.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 54% (28/52) (95% CI 40–68) | 51% (23/45) (95% CI 36–62) | 71% (5/7) (95% CI 50–92) | 0.3158 |
| 68Ga-DOTA-peptide | 88% (23/26) (95% CI 69–97) | 92% (22/24) (95% CI 63–100) | 50% (1/2) (95% CI 25–82) | 0.0764 |
| P-value | 0.0025 | 0.0008 | 0.5708 | |
| PET-CT . | Detection rate (SUVmax cut-off: 1.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 81% (42/52) (95% CI 68–93) | 81% (36/45) (95% CI 66–92) | 86% (6/7) (95% CI 53–97) | 0.7213 |
| 68Ga-DOTA-peptide | 100% (26/26) (95% CI 81–100) | 100% (24/24) (95% CI 79–100) | 50% (1/2) (95% CI 25–82) | 0.0004 |
| P-value | 0.0166 | 0.0188 | 0.2840 | |
| PET-CT . | Detection rate (SUVmax cut-off: 1.5) . | P-value . | ||
|---|---|---|---|---|
| . | All PCs . | TCs . | ACs . | . |
| 18F-FDG | 81% (42/52) (95% CI 68–93) | 81% (36/45) (95% CI 66–92) | 86% (6/7) (95% CI 53–97) | 0.7213 |
| 68Ga-DOTA-peptide | 100% (26/26) (95% CI 81–100) | 100% (24/24) (95% CI 79–100) | 50% (1/2) (95% CI 25–82) | 0.0004 |
| P-value | 0.0166 | 0.0188 | 0.2840 | |
ACs: atypical carcinoids; CI: confidence interval; CT: computed tomography; FDG: 18Fluorodeoxyglucose; PCs: pulmonary carcinoids; PET: positron emission tomography; SUVmax: maximum standardized uptake value; TCs: typical carcinoids.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
